Source: Global Banking & Finance Review (issue 66)Date: 7, October 2024Chinese multinational conglomerate Fosun International Limited is a global innovation-driven consumer group whose mission is “creating happier lives for families worldwide.” Since its inception in 1992, Fosun has accumulated profound technology and innovation capabilities and a significant indus

(2 October 2024, Hong Kong) Fosun International Limited (HKEX stock code: 00656, “FosunInternational”, “Fosun” or “the Company”) has successfully completed asustainability-linked syndicated loan amounting to USD888 million. The loan wasinitially launched earlier this year in May with first close of USD603 million,followed by Greenshoe accessions. The final size r

The international rating agency has upgraded the insurer ratings to A+ and A in the long-term.Lisbon, September 27, 2024.The American rating agency Fitch announced today that it has upgraded Fidelidade’s ratings from A to A+ (IFS – Insurer Financial Strength) and from A- to A (IDR – Issuer Default Rating), maintaining a stable outlook. These are the highest Fitch

·HANSIZHUANG (serplulimab) is the world’s first anti-PD-1 mAb for first-line treatment of ES-SCLC -·HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 monoclonal antibody available in Europe for first-line treatment of ES-SCLC -·HANSIZHUANG (serplulimab) has already been approved in China, Indonesia, Cambodia, and Thailand, benefit

(September 10, 2024, Shanghai, China) On September 9, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; Stock Code: 600196.SH; 02196.HK) announced that the Biologics License Application (“BLA”) for the licensed product RT002 (DaxibotulinumtoxinA-lanm, Chinese trademark:达希斐^®, English trademark: DAXXIFY^®, hereina

Hang Seng Indexes Company recently announced its latest Sustainability Ratings of listed companies. Fosun International Limited (HKEX stock code: 00656, “Fosun International”) with its outstanding sustainability performance, has received its rating of AA- for two consecutive years, reflecting the high recognition of Fosun International’s performance in the ESG (Environmental

In the first half of 2024, the global macroeconomic environment remained challenging. However, Fosun International (00656), which recently announced its interim results, steadfastly pushed forward its strategic focus. As a result, its four core subsidiaries, namely Yuyuan, Fosun Pharma, Fosun Insurance Portugal and Fosun Tourism Group (“FTG”),

On 29 August 2024, Guo Guangchang, Chairman of Fosun International stated at the Fosun International 2024 interim results presentation that Fosun aims to build a consumer group centered on core industries, ensuring more predictable development and profits. At both the group level and within each business unit, Fosun is committed to creating corporate value for

Fosun International Announces 2024 Interim Results: Powered by Core Strengths, Focus on Core Businesses and Reinforce Organic Growth Momentum 2024 Interim Results Highlights:·Total revenue maintained growth, reaching RMB97.84 billion;·Industrial operation profit maintained growth, reaching RMB3.47 billion;·Continued focus on core businesses, with the four core subsi